Susquehanna International Group LLP Increases Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Susquehanna International Group LLP lifted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 118.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,189 shares of the company’s stock after buying an additional 11,475 shares during the quarter. Susquehanna International Group LLP’s holdings in Prestige Consumer Healthcare were worth $1,655,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC grew its holdings in Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Prestige Consumer Healthcare by 4.3% in the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after purchasing an additional 894 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Prestige Consumer Healthcare by 171.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company’s stock worth $3,665,000 after purchasing an additional 29,649 shares during the last quarter. Diversify Wealth Management LLC raised its stake in Prestige Consumer Healthcare by 35.3% during the fourth quarter. Diversify Wealth Management LLC now owns 10,399 shares of the company’s stock valued at $770,000 after purchasing an additional 2,713 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Prestige Consumer Healthcare by 18.8% during the fourth quarter. SG Americas Securities LLC now owns 5,996 shares of the company’s stock valued at $468,000 after purchasing an additional 947 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.7%

Shares of NYSE PBH opened at $87.65 on Monday. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The firm has a 50-day simple moving average of $83.18 and a two-hundred day simple moving average of $81.45. The company has a market cap of $4.34 billion, a P/E ratio of 20.53, a PEG ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Prestige Consumer Healthcare’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $1.02 EPS. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

PBH has been the subject of a number of recent research reports. DA Davidson lifted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Royal Bank of Canada raised Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Friday. Oppenheimer lifted their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Finally, Canaccord Genuity Group increased their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This trade represents a 8.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.